摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4-三氟甲基苄基异腈酸酯 | 102422-55-9

中文名称
4-三氟甲基苄基异腈酸酯
中文别名
4-三氟甲基苄基异氰酸苯酯;4-(三氟甲基L)苄基异氰酸酯;4-三氟甲基苄基异氰酸酯;4-三氟甲基苯甲酰基异氰酸;4-(三氟甲基)苄基异氰酸酯
英文名称
4-(trifluoromethyl)benzyl isocyanate
英文别名
1-(isocyanatomethyl)-4-(trifluoromethyl)benzene
4-三氟甲基苄基异腈酸酯化学式
CAS
102422-55-9
化学式
C9H6F3NO
mdl
——
分子量
201.148
InChiKey
MBBQXHDBRSSIKS-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    212℃
  • 密度:
    1.21
  • 闪点:
    89℃

计算性质

  • 辛醇/水分配系数(LogP):
    3.5
  • 重原子数:
    14
  • 可旋转键数:
    2
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.22
  • 拓扑面积:
    29.4
  • 氢给体数:
    0
  • 氢受体数:
    5

安全信息

  • 海关编码:
    2929109000
  • 包装等级:
    III
  • 危险类别:
    6.1
  • 危险性防范说明:
    P260,P264,P280,P302+P352,P304+P340+P310,P305+P351+P338
  • 危险品运输编号:
    2206
  • 危险性描述:
    H315,H317,H319,H330,H334,H335

SDS

SDS:a34c1b5a48a1ddf7426d561e2e0917a2
查看
Material Safety Data Sheet

Section 1. Identification of the substance
Product Name: 4-(Trifluoromethyl)benzyl isocyanate
Synonyms:

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

Section 3. Composition/information on ingredients.
Ingredient name: 4-(Trifluoromethyl)benzyl isocyanate
CAS number: 102422-55-9

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C9H6F3NO
Molecular weight: 201.1

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen fluoride.

Section 11. Toxicological information
No data.

Section 12. Ecological information
No data.

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

Section 14. Transportation information
Non-harzardous for air and ground transportation.

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.


SECTION 16 - ADDITIONAL INFORMATION
N/A

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    参考文献:
    名称:
    TRPV1 vanilloid receptor antagonists with a bicyclic portion
    摘要:
    该发明揭示了以下式的化合物: 其中Y选自以下式的一组 而W、Q、n、R1、R2、R3、U1-U5的含义如描述中所给出。 该式化合物是TRPV1拮抗剂,可用作药物组合物的活性成分,用于治疗疼痛和其他通过抑制辣椒素受体TRPV1而改善的症状。
    公开号:
    EP2377850A1
  • 作为产物:
    描述:
    对三氟甲基苯腈diborane(6) 作用下, 以 四氢呋喃1,4-二氧六环 为溶剂, 反应 2.0h, 生成 4-三氟甲基苄基异腈酸酯
    参考文献:
    名称:
    芳基偶氮化物和磺酸盐使白细胞弹性蛋白酶失活。构效关系研究。
    摘要:
    报道了一系列的芳基偶氮化物和磺酸盐对人白细胞弹性蛋白酶的抑制活性。发现几种化合物是该酶的有效抑制剂。仅当特异性基团和反应性部分被两条碳链隔开时,才获得活性化合物。除磺酸盐以外,疏水基团的引入增强了这些化合物的抑制活性。离去基团的性质对抑制活性有深远的影响,化合物23和26的活性最高(分别为kobsd / [I] = 11,722和13,500 M-1 s-1)。
    DOI:
    10.1021/jm00157a034
点击查看最新优质反应信息

文献信息

  • Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
    申请人:——
    公开号:US20040157849A1
    公开(公告)日:2004-08-12
    Compounds of formula (I) 1 are novel VR1 antagonists that are useful in treating pain, inflammatory thermal hyperalgesia, urinary incontinence and bladder overactivity.
    式(I)的化合物是新颖的VR1拮抗剂,可用于治疗疼痛、炎症性热性过敏、尿失禁和膀胱过度活动。
  • [EN] ISOINDOLINONE COMPOUNDS<br/>[FR] COMPOSÉS D'ISO-INDOLINONE
    申请人:MONTE ROSA THERAPEUTICS
    公开号:WO2021069705A1
    公开(公告)日:2021-04-15
    Disclosed herein is a compound or pharmaceutically acceptable salts or stereoisomers thereof of of formula I wherein X1 is linear or branched C1-6 alkyl, C3-6 cycloalkyl, -C1-6 alkyl C3-6 cycloalkyl, C6-10 aryl, 5-10 membered heteroaryl, C1-6 alkyl C6-10 aryl, C1-6 alkyl 5-10 membered heteroaryl, wherein X1 is unsubstituted or substituted with one or more of halogen, linear or branched C1-6 alkyl, linear or branched C1-6 heteroalkyl, CF3, CHF2, -O-CHF2, -O-(CH2)2-OMe, OCF3, C1-6 alkylamino, -CN, -N(H)C(O)-C1- 6alkyl, -OC(O)-C1-6alkyl, -OC(O)-C1-4alkylamino, -C(O)O-C1-6alkyl, -COOH, - CHO, -C1-6alkylC(O)OH, -C1-6alkylC(O)O-C1-6alkyl, NH2, C1-6 alkoxy or C1-6 alkylhydroxy; X2 is hydrogen, C6-10 aryl, 5-10 membered heteroaryl, -O-(5-10 membered heteroaryl), 4-8 membered heterocycloalkyl, C1-4 alkyl 4-8 membered heterocycloalkyl, -O-(4-8 membered heterocycloalkyl), -O-C1-4 alkyl-(4-8 membered heterocycloalkyl), -OC(O)-C1-4alkyl-4-8 membered heterocycloalkyl or C6 aryloxy, wherein X2 is unsubstituted or substituted with one or more of linear or branched C1-6 alkyl, NH2, NMe2 or 5-6 membered heterocycloalkyl; n is 0, 1 or 2.
    本公开涉及一种化合物或药用可接受盐或其立体异构体,其化学式为I,其中X1为直链或支链的C1-6烷基,C3-6环烷基,-C1-6烷基C3-6环烷基,C6-10芳基,5-10成员杂芳基,C1-6烷基C6-10芳基,C1-6烷基5-10成员杂芳基,其中X1未取代或取代为一个或多个卤素,直链或支链的C1-6烷基,直链或支链的C1-6杂烷基,CF3,CHF2,-O-CHF2,-O-(CH2)2-OMe,OCF3,C1-6烷基氨基,-CN,-N(H)C(O)-C1-6烷基,-OC(O)-C1-6烷基,-OC(O)-C1-4烷基氨基,-C(O)O-C1-6烷基,-COOH,-CHO,-C1-6烷基C(O)OH,-C1-6烷基C(O)O-C1-6烷基,NH2,C1-6烷氧基或C1-6烷基羟基;X2为氢,C6-10芳基,5-10成员杂芳基,-O-(5-10成员杂芳基),4-8成员杂环烷基,C1-4烷基4-8成员杂环烷基,-O-(4-8成员杂环烷基),-O-C1-4烷基-(4-8成员杂环烷基),-OC(O)-C1-4烷基-4-8成员杂环烷基或C6芳氧基,其中X2未取代或取代为一个或多个直链或支链的C1-6烷基,NH2,NMe2或5-6成员杂环烷基;n为0、1或2。
  • TRPV1 vanilloid receptor antagonists with a bicyclic portion
    申请人:Pharmeste S.r.l.
    公开号:EP2377850A1
    公开(公告)日:2011-10-19
    The invention discloses compounds of formula I wherein Y s selected from a group of formula and W, Q, n, R1, R2, R3, U1-U5 have the meanings given in the description. The compounds of formula I are TRPV1 antagonists and are useful as active ingredients of pharmaceutical compositions for the treatment of pain and other conditions ameliorated by the inhibition of the vanilloid receptor TRPV1. 1.
    该发明揭示了以下式的化合物: 其中Y选自以下式的一组 而W、Q、n、R1、R2、R3、U1-U5的含义如描述中所给出。 该式化合物是TRPV1拮抗剂,可用作药物组合物的活性成分,用于治疗疼痛和其他通过抑制辣椒素受体TRPV1而改善的症状。
  • Novel Carbamates as Potent Histamine H<sub>3</sub> Receptor Antagonists with High <i>in Vitro</i> and Oral <i>in Vivo</i> Activity<sup>,</sup>
    作者:Holger Stark、Katja Purand、Xavier Ligneau、Agnès Rouleau、Jean-Michel Arrang、Monique Garbarg、Jean-Charles Schwartz、Walter Schunack
    DOI:10.1021/jm9507688
    日期:1996.1.1
    their H3 receptor antagonist activity. Different chain lengths and various substituents possessing different electronic and steric parameters were introduced and structure-activity relationships established. In different functional tests, the new antagonists showed high H3 receptor antagonist potencies in vitro (-log Ki values of 6.4-8.4) at synaptosomes of rat cerebral cortex and low activities at histamine
    已知的组胺H3受体拮抗剂burimamide,thioperamide,clobenpropit和相关的homogenamine thioamide衍生物被用作模板,以寻找新的线索。通过用相应的异氰酸酯或氨基甲酰氯处理醇,以高收率制备了结构上被描述为3-(1H-咪唑-4-基)丙醇的氨基甲酸酯衍生物的新型组胺H3受体拮抗剂,并研究了它们的H3受体拮抗剂活性。介绍了不同的链长和具有不同的电子和空间参数的各种取代基,并建立了结构-活性关系。在不同的功能测试中,新的拮抗剂在体外显示出较高的H3受体拮抗剂效价(对数Ki值为6.4-8。4)在大鼠大脑皮层的突触小体,组胺H1和H2受体亚型的活性低。口服给药后,还筛选了它们在小鼠中的中心体内活性。最有前途的化合物(2、16、19)的ED(50)值约为1-2 mg / kg,因此是治疗H3受体依赖性疾病的潜在药物。一些新颖的氨基甲酸酯衍生物是具有高体外和体内活性的H
  • A three-component reaction of phosphorus ylides with isocyanates: facile synthesis of 2-amino-3-carboxylate-4-quinolones
    作者:Kaki Raveendra Babu、Wendan Han、Jian-Bo Chen、Yang Li、Yuhai Tang、Wenquan Zhang、Wenbo Xu、Silong Xu
    DOI:10.1039/d0cc01401j
    日期:——
    A three-component reaction between one molecule of phosphorus ylides (P-ylides) and two molecules of isocyanates for the rapid assembly of 2-amino-3-carboxylate-4-quinolones is described. The mechanism may involve the addition of a P-ylide to an isocyanate followed by 1,3-H shift to form a carbamoyl stabilized P-ylide. The intermediate then reacts with another aryl isocyanate via Wittig/ketenimine-ketene
    描述了一个分子的磷化磷化物(P-酰基化物)和两个分子的异氰酸酯之间的三组分反应,用于快速组装2-氨基-3-羧酸酯-4-喹诺酮。该机理可包括向异氰酸酯中添加P-内酯,然后进行1,3-H转变以形成氨基甲酰基稳定的P-内酯。然后该中间体通过Wittig /酮亚胺-酮重排/6π-电环化/ 1,3-H转移与另一种异氰酸芳基酯反应,最终得到4-喹诺酮。
查看更多

同类化合物

(βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-盐酸沙丁胺醇 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (R)富马酸托特罗定 (R)-(-)-盐酸尼古地平 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[((6-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-3-(叔丁基)-4-(2,6-二苯氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (R)-2-[((二苯基膦基)甲基]吡咯烷 (N-(4-甲氧基苯基)-N-甲基-3-(1-哌啶基)丙-2-烯酰胺) (5-溴-2-羟基苯基)-4-氯苯甲酮 (5-溴-2-氯苯基)(4-羟基苯基)甲酮 (5-氧代-3-苯基-2,5-二氢-1,2,3,4-oxatriazol-3-鎓) (4S,5R)-4-甲基-5-苯基-1,2,3-氧代噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4-溴苯基)-[2-氟-4-[6-[甲基(丙-2-烯基)氨基]己氧基]苯基]甲酮 (4-丁氧基苯甲基)三苯基溴化磷 (3aR,8aR)-(-)-4,4,8,8-四(3,5-二甲基苯基)四氢-2,2-二甲基-6-苯基-1,3-二氧戊环[4,5-e]二恶唑磷 (2Z)-3-[[(4-氯苯基)氨基]-2-氰基丙烯酸乙酯 (2S,3S,5S)-5-(叔丁氧基甲酰氨基)-2-(N-5-噻唑基-甲氧羰基)氨基-1,6-二苯基-3-羟基己烷 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-双(2,6-二甲氧基苯基)-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2S)-(-)-2-{[[[[3,5-双(氟代甲基)苯基]氨基]硫代甲基]氨基}-N-(二苯基甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[[((1R,2R)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2-硝基苯基)磷酸三酰胺 (2,6-二氯苯基)乙酰氯 (2,3-二甲氧基-5-甲基苯基)硼酸 (1S,2S,3S,5S)-5-叠氮基-3-(苯基甲氧基)-2-[(苯基甲氧基)甲基]环戊醇 (1-(4-氟苯基)环丙基)甲胺盐酸盐 (1-(3-溴苯基)环丁基)甲胺盐酸盐 (1-(2-氯苯基)环丁基)甲胺盐酸盐 (1-(2-氟苯基)环丙基)甲胺盐酸盐 (-)-去甲基西布曲明 龙胆酸钠 龙胆酸叔丁酯 龙胆酸 龙胆紫 龙胆紫 齐达帕胺 齐诺康唑 齐洛呋胺 齐墩果-12-烯[2,3-c][1,2,5]恶二唑-28-酸苯甲酯 齐培丙醇 齐咪苯 齐仑太尔 黑染料 黄酮,5-氨基-6-羟基-(5CI) 黄酮,6-氨基-3-羟基-(6CI) 黄蜡,合成物 黄草灵钾盐